

Novel TEER repair device meets primary endpoint in treating degenerative mitral regurgitation

September 19 2022



Credit: Pixabay/CC0 Public Domain

Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for



degenerative mitral regurgitation (DMR) found that the PASCAL transcatheter valve repair system was non-inferior compared with MitraClip in patients with significant symptomatic DMR who are not eligible for mitral valve surgery.

Findings from the CLASP IID trial were reported today at TCT 2022, the 34th annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Severe DMR is associated with a <u>poor prognosis</u>, including a higher mortality rate, increased heart failure hospitalizations, and impaired functional and quality-of-life outcomes. Medical therapy has a limited role and in the current guidelines, surgical mitral valve repair is recommended with proven efficacy and a well-established safety profile for DMR <u>patients</u> who are symptomatic and/or have impaired left ventricular systolic function.

However, patients may be undertreated due to high operative risk, under referral, and aversion to surgery. In addition, transcatheter edge-to-edge repair with MitraClip may not be suitable or ideal for all anatomies.

New transcatheter options are emerging for patients who are not candidates for surgery. The CLASP IID trial was a prospective, multicenter, international, randomized controlled trial to evaluate the safety and effectiveness of the PASCAL transcatheter valve repair system compared with the MitraClip system in patients with significant symptomatic DMR.

Patients with 3+ or 4+ DMR at prohibitive surgical risk were considered for enrollment. Those who were deemed candidates for TEER with both systems were randomized to undergo treatment with the PASCAL repair system or the MitraClip system at a 2:1 ratio.



The primary safety endpoint was a composite major adverse event (MAE) rate at 30 days including cardiovascular mortality, stroke, <u>myocardial infarction</u>, new need for renal replacement therapy, severe bleeding, and non-elective mitral valve re-intervention (either percutaneous or surgical).

Echocardiograms were collected at baseline, during the procedure, discharge, and all follow-up visits of 30 days, six months, and annually through five years.

The analysis was completed at 180 patients in an adaptive Bayesian design. Patients were randomized at 43 sites in the United States, Canada, and Europe between November 2018 and December 2021 (117 PASCAL, 63 MitraClip). At 30 days, the rate of MAE was 3.4% for the PASCAL system versus 4.8% for the MitraClip system (Difference -1.3%, 95% CI 5.1%).

The primary effectiveness endpoint was the proportion of patients with MR \leq 2+ at six months (96.5% for PASCAL versus 96.8% for MitraClip, Difference -0.3%, 95% CI -6.2%). In addition, patients in both treatment groups had significant improvements in functional and quality-of-life outcomes (p

Citation: Novel TEER repair device meets primary endpoint in treating degenerative mitral regurgitation (2022, September 19) retrieved 4 May 2024 from <u>https://medicalxpress.com/news/2022-09-teer-device-primary-endpoint-degenerative.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.